1. Home
  2. FEMY vs NSRX Comparison

FEMY vs NSRX Comparison

Compare FEMY & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Femasys Inc.

FEMY

Femasys Inc.

HOLD

Current Price

$0.47

Market Cap

23.2M

Sector

Health Care

ML Signal

HOLD

NSRX

Nasus Pharma Ltd. Ordinary Shares

HOLD

Current Price

$3.18

Market Cap

25.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FEMY
NSRX
Founded
2004
2019
Country
United States
Israel
Employees
N/A
7
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.2M
25.8M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
FEMY
NSRX
Price
$0.47
$3.18
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
3
Target Price
$5.50
$19.67
AVG Volume (30 Days)
363.1K
107.6K
Earning Date
05-08-2026
03-25-2026
Dividend Yield
N/A
N/A
EPS Growth
44.71
N/A
EPS
N/A
N/A
Revenue
$2,293,313.00
N/A
Revenue This Year
$105.16
N/A
Revenue Next Year
$200.23
N/A
P/E Ratio
N/A
N/A
Revenue Growth
40.77
N/A
52 Week Low
$0.31
$1.98
52 Week High
$1.16
$9.99

Technical Indicators

Market Signals
Indicator
FEMY
NSRX
Relative Strength Index (RSI) 61.01 53.67
Support Level $0.33 $2.16
Resistance Level $0.58 $4.49
Average True Range (ATR) 0.03 0.50
MACD 0.01 0.05
Stochastic Oscillator 94.53 40.97

Price Performance

Historical Comparison
FEMY
NSRX

About FEMY Femasys Inc.

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

About NSRX Nasus Pharma Ltd. Ordinary Shares

Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.

Share on Social Networks: